NervGen Pharma Corp.

As of December 31, 2025, NervGen Pharma Corp. has 79.65M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, NervGen Pharma Corp. maintains a current ratio of 1.16, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -206.66, reflecting losses generated across the asset base.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -3.53: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.30, meaning NervGen Pharma Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2025, NervGen Pharma Corp. has an Altman Z-Score of 4.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.